Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XAVIER trial of intravesical Xeomin with the Vibe delivery system for female idiopathic overactive bladder
2022-501759-95-00Phase 2Completed
- Sponsor
- Vensica Therapeutics
- Start
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of botulinum toxin type A in overactive bladder (OAB) (2 arms), sponsored by Vensica Therapeutics. Primary endpoints: Drug and device related adverse events and Usability questionnaires. Started Mar 2023; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2022-501759-95-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501759-95-00.